Therapeutic | Zanolimumab |
Target | CD4 |
Heavy Chain | QVQLQQWGAGLLKPSETLSLTCAVYGGSFSGYYWSWIRQPPGKGLEWIGEINHSGSTNYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCARVINWFDPWGQGTLVTVSS |
Light Chain | DIQMTQSPSSVSASVGDRVTITCRASQDISSWLAWYQHKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPYTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | Medarex HuMAb Mouse |
INN Year Proposed | 2004 |
INN Year Recommended | 2004 |
Companies Involved | Emergent BioSolutions, Genmab |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Cutaneous T-cell lymphoma, Peripheral T-cell lymphoma, Psoriasis, Rheumatoid arthritis |
Notes |